There is a remarkable decrease in the secrecy outage probability when we increase LA from 1 to 4. This shows the improvement in performance from transmit diversity provided by TAS at Alice.
There is a remarkable decrease of mean PP with age (see upper diagram of 7), and also a notable dependence on age of the interrelations between cardiorespiratory phase recurrence and binary pattern recurrence (see Table 1).
As shown in Fig. 1B, there is a remarkable decrease in iMFI of CD4+BrdU+ in the absence of l-arginine (BALB/c: 392.2±32.6 versus 24.2±1.9, p<0.05; CBA: 133.1±11.8 versus 25.5±1.5, p<0.05), demonstrating that both the magnitude and the quality of the proliferative response of antigen-specific CD4+ T cells are greatly impaired in the absence of l-arginine.
Immediately after addition of nanoparticles, there was a remarkable decrease in the intensity of the absorption peak at 400 nm, and at the same time, a new peak at 298 nm appeared indicating the formation of reduction product, 4-AP.
There was a remarkable decrease in the optimum cure time (tc90) and the scorch time (ts2), which was associated with an increase in the cure rate index (CRI), with filler loading up to 30 phr in the different blend ratios.
Nevertheless, the number of live cells at low and intermediate MOI was only slightly lower (80% and 71%, respectively) than the non-infected control cells (91%), but there was a remarkable decrease in the number of living DCs after infection at the highest MOI (13%; Fig. 1).
There was a remarkable decrease of osteo/odontogenic genes at different time points and 5(c)).
However, there was a remarkable decrease in photosynthetic capacity, and chlorosis and browning of leaves.
Moreover, there was a remarkable decrease in lung weight after nifuroxazide treatment compared with the untreated control.
In our patient, there was a remarkable decrease in DHEAS and elevation in progesterone, suggesting a direct adrenal action of sorafenib, namely, 21-hydroxylase and 17-hydroxylase inhibition.
There was a remarkable decrease in the mortality of children under age 5 and infant mortality in the 3 years after the introduction of the BPHS, from 2003 to 2006: the under-5 mortality rate decreased by 25%, from 257 to 192 per 1,000, and the infant mortality rate declined from 165 to 129 per 1,000 live births.
